IMS Health will give AstraZeneca access to anonymized electronic health records from Europe that show clinical outcome and economic and treatment patterns in an effort to help the drugmaker distinguish its products. "Our new agreement with IMS Health ... is part of AstraZeneca's long-term investment into building industry-leading [real-world evidence] capabilities around the world," said Lynn Shepherd, AZ's director of media relations and corporate initiatives.

Related Summaries